XML 23 R5.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities:      
Net income (loss) $ (7,038,772) $ (8,049,815) $ (1,003,938)
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:      
Depreciation and amortization expense 2,982,703 2,647,753 2,396,908
Deferred tax expense 81,886 4,206,753 619,580
Share-based compensation 1,364,698 1,115,063 852,102
Share-based compensation (foundation contribution) 0 372,500 0
Excess tax (benefit) expense derived from exercise of stock options (81,886) (91,109) 1,026,413
Noncash interest expense 99,883 77,911 84,539
Noncash investment gains (168,440) (52,012) (74,015)
Net changes in assets and liabilities affecting operating activities:      
Accounts receivable 550,863 (1,064,985) (1,253,007)
Inventories 460,505 (1,366,118) (1,101,586)
Prepaid, other current assets and other assets 712,149 (1,074,369) (1,556,282)
Accounts payable and other current liabilities 4,308,706 2,307,617 191,901
Other long-term liabilities (159,558) 413,097 386,863
Net cash provided by (used in) operating activities 3,112,737 (557,714) 569,478
Cash flows from investing activities:      
Additions to property and equipment (455,569) (275,960) (130,872)
Additions to intangible assets (3,819,486) (1,213,110) (2,000,226)
Cash paid for acquisition (20,000,000) 0 0
Proceeds from sale of marketable securities 16,663,232 13,381,061 4,489,111
Purchases of marketable securities (20,112,995) (2,379,414) (5,473,092)
Net cash provided by (used in) investing activities (27,724,818) 9,512,577 (3,115,079)
Cash flows from financing activities:      
Borrowings on line of credit 56,000,000 24,500,000 2,400,000
Repayments on line of credit (45,800,000) (18,800,000) 0
Repurchase of common shares (2,879,426) (3,724,375) (2,520,715)
Payments of deferred equity offering costs (383,310) (27,950) 0
Exercise of stock options 200,909 0 0
Excess tax (expense) benefit derived from exercise of stock options 0 0 (1,026,413)
Net cash provided by (used in) financing activities 7,138,173 1,947,675 (1,147,128)
Net increase (decrease) in cash and cash equivalents (17,473,908) 10,902,538 (3,692,729)
Cash and cash equivalents, beginning of year 45,412,868 34,510,330 38,203,059
Cash and cash equivalents, end of year 27,938,960 45,412,868 34,510,330
Net cash paid (refunded) during the year for:      
Interest 95,965 14,993 21,853
Income taxes 15,441 18,000 (8,359)
Noncash investing and financing activities:      
Change in unpaid invoices for purchases of intangibles (539,467) (513,481) (1,179,394)
Deferred offering costs included in accounts payable and other accrued expenses 0 97,254 0
Non cash increase in liabilities related to acquisition (see Note 3) $ 14,034,000 $ 0 $ 0